Trials / Completed
CompletedNCT01153971
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
An Open-label Study of Fludarabine and Cyclophosphamide Plus MabThera Followed by Maintenance With MabThera on Failure-free Survival in Treatment-naïve Patients With Advanced Indolent B-cell Nonfollicular Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera. The anticipated time on study treatment is 1-2 years, and the target sample size is \<100 individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rituximab | 1 |
Timeline
- Start date
- 2005-07-20
- Primary completion
- 2010-09-24
- Completion
- 2010-09-24
- First posted
- 2010-06-30
- Last updated
- 2017-08-01
- Results posted
- 2014-08-21
Locations
15 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT01153971. Inclusion in this directory is not an endorsement.